Research
Hormonal
Oxidative stress contributes to aging and age-related diseases by altering epigenetic markers, including DNA methylation and histone modifications, leading to cellular senescence and organ dysfunction.
Focus on reducing oxidative stress through a healthy diet, regular exercise, and avoiding environmental toxins. These lifestyle choices may help maintain epigenetic health and slow the progression of age-related diseases.
GoodSupportsHIGH confidence
Mechanistically, it is well accepted that the accumulation of intracellular damage determined by reactive oxygen species (ROS) might orchestrate the progressive loss of control over biological homeostasis and the functional impairment typical of aged tissues. Alteration of epigenetic enzyme activity, histone modifications and DNA-methylation is, in fact, typically associated with the ageing process.
Why this rating
The paper is a comprehensive review citing numerous studies across multiple organ systems and species.
Source
Oxidative Stress and Epigenetic Regulation in Ageing and Age-Related Diseases
Chiara Cencioni et al. · International Journal of Molecular Sciences · 2013
DOI 10.3390/ijms140917643
narrative_reviewCited 222×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Caloric restriction extends lifespan and delays age-related decline by activating SIRT1, which deacetylates and activates eNOS to improve vascular function and reduce oxidative stress.Moderate
- Resveratrol supplementation mimics the effects of caloric restriction by activating SIRT1, leading to metabolic and vascular benefits in obese humans.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →